Compare HCI & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HCI | AVDL |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | Ireland |
| Employees | 552 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | N/A | 1996 |
| Metric | HCI | AVDL |
|---|---|---|
| Price | $173.90 | $21.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $230.00 | $18.38 |
| AVG Volume (30 Days) | 166.1K | ★ 2.8M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | ★ 32.29 | N/A |
| EPS | ★ 15.80 | N/A |
| Revenue | ★ $816,578,000.00 | $248,517,000.00 |
| Revenue This Year | $19.65 | $65.47 |
| Revenue Next Year | $9.97 | $30.88 |
| P/E Ratio | $10.94 | ★ N/A |
| Revenue Growth | 8.75 | ★ 79.88 |
| 52 Week Low | $106.89 | $6.38 |
| 52 Week High | $210.50 | $23.57 |
| Indicator | HCI | AVDL |
|---|---|---|
| Relative Strength Index (RSI) | 41.79 | 58.90 |
| Support Level | $168.93 | $21.32 |
| Resistance Level | $181.51 | $21.62 |
| Average True Range (ATR) | 5.64 | 0.29 |
| MACD | -0.05 | -0.31 |
| Stochastic Oscillator | 36.92 | 6.90 |
HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are insurance operations, TypTap Group, reciprocal exchange operations, real estate operations, and corporate and other. It derives key revenue from the HCPCI Insurance operation segment.
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.